| Literature DB >> 34397790 |
Xiao-Long Liu1, Rong-Chun Wang2, Yi-Yang Liu1, Hao Chen1, Chen Qi2, Li-Wen Hu2, Jun Yi2, Wei Wang3.
Abstract
BACKGROUND AND OBJECTIVES: Postoperative major complications after esophageal cancer resection vary and may significantly impact long-term outcomes. This study aimed to build an individualized nomogram to predict post-esophagectomy major morbidity.Entities:
Mesh:
Year: 2021 PMID: 34397790 PMCID: PMC8341312 DOI: 10.1097/MD.0000000000026189
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Flowchart depicting consecutive patients and reasons for exclusion from the present study.
Univariate and multivariate logistic regression models in the development group.
| Univariate analysis OR (95% CI) | Multivariate analysis OR (95% CI) | |
| Age | 1.04 (1.01–1.07) .0077 | 1.05 (1.01–1.08) .0087 |
| Smoking | 2.57 (1.63–4.06) <.0001 | 2.45 (1.47–4.09) .0006 |
| Dinking | 1.37 (0.88–2.14) .1638 | |
| Sex | 1.75 (0.94–3.27) .0793 | |
| DM | 0.85 (0.36–2.04) .7236 | |
| HTN | 1.26 (0.79–2.02) .3348 | |
| COPD | 3.04 (0.75–12.37) .1207 | |
| CHD | 5.94 (2.14–16.50) .0006 | 4.94 (1.58–15.49) .0061 |
| Stroke | 1.27 (0.54–2.99) .5878 | |
| Dysphagia | 5.08 (2.64–9.76) <.0001 | 5.82 (2.81–12.03) <.0001 |
| BMI | 0.90 (0.84–0.97) .0038 | 0.90 (0.83–0.98) .0111 |
| Operation time | 1.50 (1.22–1.83) <.0001 | 1.48 (1.18–1.85) .0006 |
| Tumor size | 1.23 (1.08–1.41) .0023 | 1.23 (1.06–1.43) .0074 |
| Location | ||
| Upper | 1.0 | |
| Middle | 2.25 (0.64–7.91) .2069 | |
| Lower | 1.54 (0.42–5.57) .5133 | |
| ASA | ||
| 1 | 1.0 | |
| 2 | 0.57 (0.33–0.99) .0449 | |
| 3 | 2.12 (0.92–4.89) .0766 | |
| 4 | 0.54 (0.06–4.70) .5773 | |
| Type of operation | ||
| Open operation | 1.0 | |
| MIE | 1.95 (1.20–3.18) .0072 | |
| RAMIE | 2.79 (1.42–5.49) .0029 | |
| Anastomosis | ||
| Cervical | 1.0 | |
| Intrathoracic | 0.67 (0.40–1.11) .1225 | |
| Lymph no. | 1.02 (1.00–1.05) .0323 | |
| Tstage | ||
| TIS | 1.0 | |
| T1 | 0.87 (0.26–3.00) .8317 | |
| T2 | 0.70 (0.21–2.39) .5689 | |
| T3 | 1.30 (0.40–4.19) .6655 | |
| T4 | 1.12 (0.20–6.43) .8947 | |
| Nstage | ||
| N0 | 1.0 | |
| N1 | 1.16 (0.69–1.94) .5743 | |
| N2 | 1.28 (0.66–2.49) .4700 | |
| N3 | 2.43 (0.53–11.16) .2543 | |
| NC | 0.91 (0.47–1.76) .7693 | |
Baseline characteristics of the development group and validation group (n = 599).
| Group | Development (n = 420) | Validation (n = 179) | |
| Age (median, Q1–Q3) | 64.00 (59.00–69.00) | 65.00 (60.00–70.00) | .264 |
| BMI, kg/m2 (Median, Q1–Q3) | 23.00 (21.00–25.00) | 23.00 (21.00–25.00) | .746 |
| Smoking history | .835 | ||
| No | 219 (52.14%) | 95 (53.07%) | |
| Yes | 201 (47.86%) | 84 (46.93%) | |
| Dinking history | .659 | ||
| No | 250 (59.52%) | 110 (61.45%) | |
| Yes | 170 (40.48%) | 69 (38.55%) | |
| Sex | .219 | ||
| Female | 80 (19.05%) | 42 (23.46%) | |
| Male | 340 (80.95%) | 137 (76.54%) | |
| DM | .588 | ||
| No | 389 (92.62%) | 168 (93.85%) | |
| Yes | 31 (7.38%) | 11 (6.15%) | |
| HTN | .289 | ||
| No | 293 (69.76%) | 117 (65.36%) | |
| Yes | 127 (30.24%) | 62 (34.64%) | |
| COPD | .495 | ||
| No | 412 (98.10%) | 174 (97.21%) | |
| Yes | 8 (1.90%) | 5 (2.79%) | |
| CHD | .938 | ||
| No | 403 (95.95%) | 172 (96.09%) | |
| Yes | 17 (4.05%) | 7 (3.91%) | |
| Stroke history | .349 | ||
| No | 393 (93.57%) | 171 (95.53%) | |
| Yes | 27 (6.43%) | 8 (4.47%) | |
| Dysphagia | .188 | ||
| No | 377 (89.76%) | 154 (86.03%) | |
| Yes | 43 (10.24%) | 25 (13.97%) | |
| Tumor location | .224 | ||
| Upper | 20 (4.76%) | 15 (8.38%) | |
| Middle | 250 (59.52%) | 103 (57.54%) | |
| Lower | 150 (35.71%) | 61 (34.08%) | |
| ASA | .932 | ||
| 1 | 274 (65.24%) | 121 (67.60%) | |
| 2 | 115 (27.38%) | 45 (25.14%) | |
| 3 | 25 (5.95%) | 11 (6.15%) | |
| 4 | 6 (1.43%) | 2 (1.12%) | |
| Operation time, h | 3.90 (2.90–4.60) | 3.60 (2.80–4.50) | .761 |
| Tumor size, cm | 3.50 (2.30–4.50) | 3.00 (2.20–4.35) | .720 |
| Lymph no. | 20.00 (14.00–26.00) | 21.00 (15.00–27.50) | .351 |
| Type of operation | .278 | ||
| Open operation | 200 (47.62%) | 81 (45.25%) | |
| MIE | 170 (40.48%) | 68 (37.99%) | |
| RAMIE | 50 (11.90%) | 30 (16.76%) | |
| Anastomosis | .269 | ||
| Cervical | 296 (70.48%) | 118 (65.92%) | |
| Intrathoracic | 124 (29.52%) | 61 (34.08%) | |
| Tstage | .623 | ||
| TIS | 16 (3.81%) | 8 (4.47%) | |
| T1 | 93 (22.14%) | 33 (18.44%) | |
| T2 | 111 (26.43%) | 50 (27.93%) | |
| T3 | 189 (45.00%) | 86 (48.04%) | |
| T4 | 11 (2.62%) | 2 (1.12%) | |
| Nstage | .936 | ||
| N0 | 250 (59.52%) | 104 (58.10%) | |
| N1 | 110 (26.19%) | 49 (27.37%) | |
| N2 | 53 (12.62%) | 24 (13.41%) | |
| N3 | 7 (1.67%) | 2 (1.12%) | |
| NC | .935 | ||
| No | 365 (86.90%) | 156 (87.15%) | |
| Yes | 55 (13.10%) | 23 (12.85%) |
Overall and major complications after esphogectomy.
| Complication category | Complications | No. | % |
| Overall morbidity | I–V | 218 | 36.3 |
| Clavien I | |||
| Atelectasis, vocal cord paresis or paralysisClavien II | 41 | 6.8 | |
| Pneumonia, chyle leakage, pulmonary embolus | 29 | 4.8 | |
| Major morbidity | III–V | 148 | 24.6 |
| Clavien III | 72 | 12 | |
| Anastomotic leak | 48 | 8 | |
| Reoperation due to thoracic duct injury | 14 | 2.3 | |
| Clavien IV | 50 | 8.3 | |
| Requiring artificial ventilation | 28 | 4.8 | |
| Heart failure | 8 | 1.3 | |
| Renal insufficiency | 3 | 0.5 | |
| Combination of at least 2 complications | 11 | 1.8 | |
| Clavien V (30-day postoperative death) | 26 | 4.3 |
Figure 2Nomogram predicting the probability of morbidity in patients after esophagectomy.
Figure 3Receiver-operating characteristic curves for validating the discrimination power of the nomogram. Development group (A) and validation group (B) (area under the curve = 0.775 vs 0.792).
Figure 4Calibration plots of the nomogram for the probability of morbidity in the development group (A) and validation group (B).
Figure 5Decision curve analysis in the development group (A) and validation group (B).